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ABSTRACT Sepsis still constitutes an unmet clinical need, which could beneﬁt from
novel adjunctive strategies to conventional antibiotic therapy. The soluble form of
the scavenger-like human CD6 lymphocyte receptor (shCD6) binds to key patho-
genic components from Gram-positive and -negative bacteria and shows time- and
dose-dependent efﬁcacy in mouse models of monobacterial sepsis. The objective of
the present work was to demonstrate the effectiveness of infusing mouse and hu-
man sCD6 by different systemic routes, either alone or as adjunctive therapy to gold
standard antibiotics, in a lethal model of polymicrobial sepsis. To this end, C57BL/6
mice undergoing high-grade septic shock induced by cecal ligation and puncture
(CLP; 90% lethality) were infused via the intraperitoneal (i.p.) or intravenous (i.v.)
route with shCD6 at different doses and time points, either alone or in combination
with imipenem/cilastatin (I/C) at a dose of 33 mg/kg of body weight every 8 h. Sig-
niﬁcantly reduced mortality and proinﬂammatory cytokine levels were observed by
i.p. infusion of a single shCD6 dose (1.25 mg/kg) 1 h pre- or post-CLP. When using
the i.v. route, mice survival was signiﬁcantly extended by starting shCD6 infusion at
later time points post-CLP (up to 6 h after CLP). Signiﬁcant adjunctive effects on
mouse survival were observed by i.p. or i.v. infusion of shCD6 in combination with
i.p. I/C post-CLP. Similar results were obtained in mice expressing high sustained lev-
els (5 to 10 g/ml) of mouse sCD6 in serum by means of transduction with hepato-
tropic adeno-associated virus (AAV). Taken together, the data support the conserved
antibacterial effects of human and mouse sCD6 and their use as adjunctive therapy
in experimental models of complex and severe polymicrobial sepsis.
KEYWORDS soluble CD6, cecal ligation and puncture, polymicrobial peritonitis,
scavenger receptors, sepsis, septic shock, adjunctive therapy
Sepsis, severe sepsis, and septic shock still present unmet clinical needs with apredicted increase in occurrence and a huge socioeconomic burden as a result
of population aging, increases in invasive medical procedures, the emergence of
multidrug-resistant (MDR) bacteria, and the increased prevalence of chronic diseases
(1). Sepsis is considered a dysregulated systemic inﬂammatory response syndrome
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caused by an infection, leading to an overwhelming and sustained proinﬂammatory
state and, if unresolved, to multiorgan dysfunction (MOD) and death (2). Such a
dysfunctional host inﬂammatory response is triggered by conserved structures present
on microbial cell walls named pathogen-associated molecular patterns (PAMPs). PAMPs
are essential compounds for the microbial physiology, among which are lipopolysac-
charide (LPS) from Gram-negative (G) bacteria, lipoteichoic acid (LTA) and peptidogly-
can (PGN) from Gram-positive (G) bacteria, -glucan and mannan from fungi, and
single- or double-stranded nucleic acids from viruses (3). Detection of PAMPs is
accomplished by germ line-encoded, nonclonally distributed, and nonpolymorphic
pattern recognition receptors (PRRs) present on immune cells. PRRs belong to different
structural and functional protein receptor families (e.g., Toll-like receptors [TLR], scav-
enger receptors, or C-type lectins) and contribute not only to pathogen detection but
also to engagement and modulation of innate and adaptive immune responses (4).
The CD6 glycoprotein is a lymphocyte surface receptor belonging to the scavenger
receptor cysteine-rich superfamily (SRCR-SF)—an ancient and highly conserved group
of PRRs characterized by the presence of one or several repeats of a 90- to 110-amino-
acid-long cysteine-rich globular domain (5, 6). CD6 is expressed mainly by all T cells but
also by a subset of B (B1a) and of natural killer (NK) cells and some hematopoietic cell
precursors and brain cells (5, 6). CD6 has an extracellular region composed by three
tandem SRCR domains and a cytoplasmic tail suitable for signal transduction. Indeed,
CD6 is physically associated with the T-cell receptor (TCR) complex (7) and plays
relevant roles in regulating some T-cell developmental and activation/differentiation
processes (8, 9). The latter is achieved mainly through interaction with its main reported
ligand, namely, CD166/ALCAM (where ALCAM stands for activated leukocyte cell
adhesion molecule)—an adhesion molecule of the immunoglobulin superfamily (10).
Aside from such an endogenous ligand, the CD6 ectodomain also interacts with certain
PAMPs from G (LPS) and G (LTA and PGN) bacteria (11, 12). Interestingly, the
dissociation constants (Kd) of the CD6-LPS (2.69  108  0.32  108 M), CD6-LTA
(0.17  0.02 M), and CD6-PGN (1.1  0.1 nM) interactions are relatively high (11, 12)
and of magnitude similar to that reported for CD14, the main macrophage receptor for
those bacterial components (13, 14). Accordingly, the prophylactic infusion of a recom-
binant soluble form of human CD6 (rshCD6) signiﬁcantly reduces mortality and levels
of proinﬂammatory cytokines (interleukin-1 beta [IL-1], IL-6, and tumor necrosis factor
alpha [TNF-]) in serum in mouse models of septic shock induced by G (LTA plus PGN)
and G (LPS) bacterial endotoxins, as well as whole live G (Staphylococcus aureus) and
G (Acinetobacter baumannii) bacteria, independently of their MDR phenotype (11, 12).
Several mechanisms of action account for the antibacterial properties of rhsCD6, all of
them related to innate immunity. So, rshCD6 interferes with the sensing of bacterial
PAMPs by PRRs (e.g., TLR2 and TLR4) broadly expressed on innate immune cells and
thus reduces the release of proinﬂammatory cytokines, as demonstrated by both in
vitro and in vivo evidence (11, 12). Neutralization of PAMP-mediated inﬂammation by
rshCD6 also involves aggregation of whole bacteria and of bacterial PAMPs (11), a very
basic mechanism of innate defense interfering with bacterial infection spreading and
facilitating engulfment by phagocytic cells. Finally, rshCD6 also reduces viable cell
counts and intracellular ATP production following incubation with bacterial cell sus-
pensions (12). This inhibitory effect on bacterial growth should not be taken, however,
as fully indicative of direct bactericidal properties of the rshCD6 protein. Indeed, the
sepsis survival rate achieved by rshCD6 infusion upon monobacterial infection is greatly
reduced in leukopenic mice, a fact that is not observed with the use of bactericidal
antibiotics (12).
In the present report, the prophylactic and therapeutic potential of rshCD6 infusion
is further explored in the mouse model of septic shock most closely resembling the
progression and characteristics of human sepsis: intra-abdominal polymicrobial infec-
tion induced by cecal ligation and puncture (CLP) (15). Time- and dose-dependent
effects of single or repeated rshCD6 dosage by different routes are investigated, either
alone or in combination with broad-spectrum bactericidal antibiotics. By means of
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adeno-associated virus 8 (AAV8)-mediated gene delivery, the conserved antimicrobial
properties of mouse soluble CD6 (msCD6) and its prophylactic potential are also
analyzed.
RESULTS
Prophylactic effects of i.p. rshCD6 infusion in CLP-induced septic shock. Given
the reported ability of rshCD6 for targeting pathogenic factors from G (LTA, PGN) and
G (LPS) bacteria (11, 12), its potential use for prevention and/or treatment of poly-
microbial sepsis of intra-abdominal origin, namely, CLP, was tested. Based on previous
results obtained in a mouse model of monobacterially induced peritonitis (12), we ﬁrst
infused via the i.p. route a single dose of rshCD6 (1.25 mg/kg of body weight) 1 h before
(1 h) CLP induction to C57BL/6 mice. As illustrated by Fig. 1A, survival was signiﬁ-
cantly increased (P  0.0067) for mice treated with rshCD6 (47.06%, n  15) in
comparison to the group treated with saline (6.52%, n  18) or with rshCD5 (11.11%,
n  9). These prophylactic effects on mouse survival were dose dependent, with doses
above 0.625 mg/kg giving statistically signiﬁcant results and reaching maximal efﬁcacy
at 2.5 mg/kg (Fig. 1B). Prophylactic infusion of rshCD6 also signiﬁcantly lowered the
levels of the proinﬂammatory cytokines IL-1, IL-6, and TNF- in plasma together with
higher levels of anti-inﬂammatory cytokine IL-10 compared to levels in the saline-
treated group (Fig. 1C). Taken together, these results indicate that prophylactic infusion
of rshCD6 has speciﬁc and dose-dependent effects on mouse survival following CLP-
induced septic shock, showing also signiﬁcant reductions on systemic inﬂammation
parameters.
Therapeutic effects of i.p. rshCD6 infusion in CLP-induced septic shock. To
further explore the putative therapeutic effects of rshCD6 infusion, time course exper-
iments were performed. As illustrated by Fig. 2A, a single infusion of rshCD6 (1.25
FIG 1 Effects of prophylactic i.p. rshCD6 infusion on CLP-induced polymicrobial septic shock. (A)
C57BL/6J mice were infused i.p. with saline (n 18), rshCD5 (1.25 mg/kg; n 9), or rshCDC6 (1.25 mg/kg;
n  15) 1 h before induction of CLP-induced septic shock. (B) C57BL/6J mice were infused with either
saline (n  21) or increasing amounts of rshCD6 (0.31 mg/kg, n  12; 0.62 mg/kg, n  10; 1.25 mg/kg,
n  17; or 2.50 mg/kg, n  5) 1 h before CLP-induced septic shock. In all panels, the average percentage
of survival was analyzed over time for each group and compared to that of the saline-treated group using
the log rank t test. (C) Levels of the indicated cytokines in plasma were monitored at the indicated time
points (4 h, 20 h) post-CLP in C57BL/6J mice prophylactically treated (1 h) with either saline (n 
10) or rshCD6 (1.25 mg/kg; n  10). Data are expressed as means  standard errors of the means (SEM)
in nanograms or picograms per milliliter, and statistical differences were evaluated using the 2-tailed
Student t test.
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mg/kg) i.p. at different times pre- and post-CLP showed statistically signiﬁcant effects
(P 0.012) on mouse survival when administered at1 h (29.03%, n 31) but not3
h (14.28%, n  14) or 6 h (17.65%, n  17) post-CLP, compared to the saline-treated
group (6.52%, n  46). The survival achieved by infusing rshCD6 at1 h was, however,
lower than that obtained at 1 h pre-CLP and was not improved by repeated dosage
at 1 h, 3 h, and 6 h post-CLP (26.32%, n  19), although the last group still
reached statistical signiﬁcance (P  0.0016) compared with the saline-treated group
(Fig. 2B). Monitoring of cytokine levels in plasma at 4 and 20 h post-CLP showed that
the mice treated with rshCD6 via i.p. 1 h post-CLP presented lower proinﬂammatory
FIG 2 Effects of therapeutic i.p. rshCD6 infusion on CLP-induced polymicrobial septic shock. (A) C57BL/6J
mice were infused i.p. with either saline (n  46) or rshCD6 (1.25 mg/kg) at different time points either
before (1 h; n  19) or after (1 h, n  31; 3 h, n  14; 6 h, n  17) CLP-induced septic shock. (B)
C57BL/6J mice were i.p. infused with a single dose of saline (n 46) or rshCD6 (1.25 mg/kg) 1 h post-CLP
(1 h, n  31) or a repeated dosage of rshCD6 (1.25 mg/kg) at 1 h, 3 h, and 6 h (136h; n 
19) after CLP-induced septic shock. In panels A and B, average percent survival was analyzed over time,
and statistical comparisons were made with regard to the saline-treated group by using the log rank t
test. (C) Levels of proinﬂammatory (TNF-, IL-1, IL-6) and anti-inﬂammatory (IL-10) cytokines in plasma
were monitored by ELISA at the indicated time points (4 h, 20 h) after CLP-induced septic shock in
C57BL/6J mice therapeutically treated (1 h) i.p. with either saline (n  10) or rshCD6 (1.25 mg/kg; n 
10). Data are expressed as means  standard deviations (SD) in nanograms or picograms per milliliter,
and statistical comparisons were made by using the 2-tailed Student t test. (D) C57BL/6J mice were
therapeutically (1 h) infused i.p. with saline (n  24), rshCD6 (1.25 mg/kg; n  18), imipenem/cilastatin
(I/C; 33 mg/kg/8 h; n  25), or a combination of the last two (n  24), and the percent average of mouse
survival was represented over time. Statistical comparisons were made with regard to the saline-treated
group by using the log rank t test.
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cytokine levels, which reached statistical signiﬁcance for IL-1 and IL-6, but not TNF-,
with no differences observed for the anti-inﬂammatory cytokine IL-10, than in the
saline-treated group (Fig. 2C). In conclusion, these results indicate that therapeutic
effects of rshCD6 infusion via the i.p. route are achieved only at early (1 h) but not at
later (3 h or 6 h) time points post-CLP induction, even when administered at
repeated dosage.
Next, the therapeutic effect of combining rshCD6 and the broad-spectrum bacteri-
cidal carbapenem imipenem/cilastatin—a ﬁrst-choice treatment in critically ill patients
with sepsis—on mouse survival post-CLP was investigated. To this end, mice subjected
to CLP were i.p. infused at 1 h with rshCD6 (1.25 mg/kg), imipenem/cilastatin (33
mg/kg/8 h), or a combination of the two. As illustrated in Fig. 2D, each of rshCD6
(26.4%, n 34; P 0.008) and imipenem/cilastatin (19%, n 21; P 0.03), given alone,
showed similar signiﬁcant effects on mouse survival compared to what was seen in the
saline-treated group. Importantly, the simultaneous administration of rshCD6 plus
imipenem/cilastatin showed additive effects on mouse survival (37.5%, n  24), which
were statistically signiﬁcant not only compared with the saline-treated group (p 
0.0001) but also compared with the group treated with only imipenem/cilastatin (P 
0.032). These additive effects would be indicative of different mechanisms of action for
the two treatments.
Therapeutic effects of i.v. rshCD6 infusion in CLP-induced septic shock. The i.p.
route is widely used for the systemic administration of compounds to animals (16),
though the route of choice for human clinical purposes is the i.v. one, a matter that can
inﬂuence systemic drug bioavailability. Accordingly, rshCD6 plasma levels differed
when a single dose (1.25 mg/kg) was administered to C57BL/6 mice either via i.p. or i.v.
As illustrated in Fig. 3A, maximal rshCD6 levels were achieved at 3 h following i.p.
infusion, and then the levels decreased to nearly basal values by 6 h. In contrast, i.v.
infusion achieved maximal and sustained levels in plasma at 1 h to 3 h, which then
declined to nearly basal levels by 6 h. Interestingly, maximal levels achieved via i.v.
administration were higher than those obtained via the i.p. route, thus supporting a
higher and more sustained systemic bioavailability for the i.v. route than for the i.p.
route.
FIG 3 Effects of therapeutic i.v. rshCD6 infusion on CLP-induced polymicrobial septic shock. (A) C57BL/6J
mice were infused i.p. (n  6, left) or i.v. (n  6, right) with rshCD6 (1.25 mg/kg), and levels of rshCD6
in plasma were determined by ELISA as mean ( SD) micrograms per milliliter. (B) C57BL/6J mice were
infused i.v. with saline (n  18) or rshCD6 (1.25 mg/kg) at different time points (1 h, n  20; 3 h, n 
10; and 6 h, n  5) after CLP-induced septic shock. (C) C57BL/6J mice were therapeutically (1 h)
infused i.v. with saline (n 24), rshCD6 (1.25 mg/kg, n 18), imipenem/cilastatin (I/C; 33 mg/kg/8 h; n
25), or a combination of the last two (n 24). In panels B and C, average survival was analyzed over time
for each group, and all the statistical comparisons were made with regard to the saline-treated group by
using the log rank t test.
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In light of these results, time course experiments exploring the therapeutic efﬁcacy
of i.v. rshCD6 infusion on CLP-induced mouse survival were performed. As shown in Fig.
3B, mouse survival was signiﬁcantly improved over that of the saline-treated group by
a single dose of i.v. rshCD6 (1.25 mg/kg) at 1 h (30%, n  20, P  0.02), but also at
3 h (20%, n  10; P  0.0405) and 6 h (40%, n  5; P  0.02) post-CLP. Although
there were not statistical signiﬁcant differences between rshCD6-treated groups at 1
h,3 h, and 6 h, the results indicate that the i.v. route extends the therapeutic effects
of rshCD6 over time. Similarly, the above-mentioned additive effects of rshCD6 plus
imipenen/cilastatin infused i.p. at1 h post-CLP on mouse survival were also extended
by administering rshCD6 via the i.v. route at the same dose and time point. As shown
in Fig. 3C, the mouse survival achieved by individual administration of imipenem/
cilastatin given i.p. at 33 mg/kg/8 h (23.5%, n  17, P  0.017) or rshCD6 given i.v. at
1.25 mg/kg (33.3%, n  15; P  0.006) was greatly improved by the combined
administration of the two agents (60%, n  15; P  0.0001) compared with survival of
the saline-treated group. Importantly, the differences in mouse survival observed
between groups receiving imipenen/cilastatin alone or combined with rshCD6 were
also statistically signiﬁcant (P  0.008).
Prophylactic effect of liver-speciﬁc AAV-mediated expression of mouse soluble
CD6 in CLP-induced septic shock. In order to achieve high and sustained circulating
levels of sCD6, a recombinant AAV8 was engineered to express a mouse sCD6 form
(AAV-rmsCD6) under the transcriptional control of a liver-speciﬁc promoter. The ratio-
nale behind using not the human but the msCD6 was that the latter would be less
immunogenic for mice and its long-term expression and function would not be
interfered with by newly appearing neutralizing antibodies. Transduction of C57BL/6
mice with AAV-rsmCD6 virus resulted in detectable rmsCD6 in plasma from day 10 on,
reaching maximal levels at days 15 to 20 (Fig. 4A). This expression system allowed
sustained expression levels of rmsCD6 in the range of 5 to 15 g/ml for periods of time
longer than 3 months. According to these results, mice were subjected to CLP-induced
septic shock 2 weeks after transduction with 1  1011 viral particles of AAV-rmsCD6 or
control AAV-Luc, and their survival was monitored over time. As illustrated in Fig. 4B,
mice treated with AAV-rmsCD6 showed a statistically signiﬁcant higher survival rate
(42.85%, n  14; P  0.0145) than did control mice treated with AAV-Luc (7.14%, n 
13). This effect was concomitant with signiﬁcant reductions in the levels of proinﬂam-
matory cytokines (TNF-, IL-1 and IL-6) in serum and increments in those of IL-10 (Fig.
4C). Importantly, therapeutic infusion of imipenem/cilastatin (33 mg/kg/8 h, i.p.) at 1
h post-CLP induced signiﬁcant increments of mouse survival in both the AAV-rsmCD6-
treated (78.57%, n  14) and AAV-Luc-treated (56.25%, n  16) groups.
DISCUSSION
Overall mortality of sepsis and septic shock remains high (35% and 60%, respec-
tively) despite signiﬁcant advances in supportive care and the availability of potent
broad-spectrum antibiotics (17). Although antibiotics constitute a necessary part of the
treatment of sepsis, they are probably not sufﬁcient to substantially reduce the
mortality associated with the MOD accompanying sepsis and septic shock. This, to-
gether with the increase in MDR bacteria, makes mandatory the search for alternative
nonantibiotic (adjunctive) strategies. Aside from improvements in supportive care,
those strategies include treatments aimed at bacterial virulence factors and/or host
inﬂammatory and immune mediators (1, 2, 17, 18). Accordingly, the present work
reports the in vivo prophylactic and therapeutic effects of the soluble ectodomain from
the scavenger-like lymphocyte receptor CD6 (sCD6) in a lethal model of polymicrobial
infection of intra-abdominal origin. The results show time- and dose-dependent effects
of sCD6 infusion on mouse survival post-CLP induction, which are concomitant with
reduced systemic inﬂammatory response. Interestingly, both human and mouse sCD6
infusion showed additive effects on mouse survival when combined with the broad-
spectrum bactericidal antibiotic imipenem/cilastatin.
Previous studies from our group indicate that sCD6 acts mainly through direct
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binding to key pathogenic factors from G (LPS) and G (LTA and PGN) bacterial cell
walls and consequently interferes with TLR2- and TLR4-mediated cytokine release
induced by them, aside from reducing bacterial growth and viability (12). Such a broad
set of bacterial binding properties makes sCD6 a suitable candidate for treating
complex polymicrobial infections as in the case of that induced by CLP. In this model,
a massive seeding of indigenous gut ﬂora (mainly bacteria, from anaerobic to faculta-
tive aerobic or aerobic) into peritoneum and systemic circulation develops the symp-
toms characteristic of peritonitis and sepsis, allowing testing of the broad-spectrum
antibacterial properties of sCD6. Not withstanding, PAMPs targeted by sCD6 are
conserved constituents of bacterial cell walls, which are essential for bacterial survival
and are not easily amenable to mutation without losing viability and/or pathogenicity.
All these properties make sCD6 a good target for alternative/adjunctive antibacterial
strategies.
The results show the induction of both prophylactic and therapeutic effects of sCD6
infusion and how they are inﬂuenced by the route of administration. By using the i.p.
route, the best results are achieved in the prophylactic mode (at 1 h pre-CLP),
although therapeutic effects were still observed at early (1 h) but not later (3 h) time
points post-CLP. Interestingly, the use of the i.v. route allowed extending the thera-
peutic effects of sCD6 up to3 h or6 h post-CLP. This would support the notion that
sCD6 acts mainly in early phases of the sepsis process and that there is no beneﬁt in
FIG 4 Effects of AAV-mediated gene delivery of rsmCD6 on CLP-induced polymicrobial septic shock. (A)
C57BL/6J mice (n  6) were treated i.v. with hepatotropic AAV coding for rsmCD6 (AAV-rsmCD6) and
bled at different time points for monitoring of rsmCD6 levels in plasma by ELISA. Data are expressed as
mean ( SD) micrograms per milliliter. (B) C57BL/6J mice i.v. treated with 1  1011 AAV-rsmCD6 or
AAV-Luc viral particles 2 weeks before CLP-induced septic shock were therapeutically (1 h) infused i.p.
with (n  15 and n  16, respectively) or without (n  14 and n  13, respectively) imipenem/cilastatin
(I/C; 33 mg/kg/8 h). Average percent survival was analyzed over time, and statistical comparisons were
made with regard to the saline-treated group by using the log rank t test. (C) Levels of the indicated
cytokines in plasma were monitored by ELISA at the indicated time points (4 h, 20 h) after
CLP-induced septic shock in C57BL/6J mice treated 2 weeks before with 1  1011 AAV-rsmCD6 (n  10)
or AAV-Luc (n  10) viral particles. Data are expressed as mean (SD) nanograms or picograms per
milliliter, and statistical comparisons were made using the 2-tailed Student t test.
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delaying and/or repeating its infusion over time. This situation recalls the reported
relationship between the delay in starting antibiotics and the eventual outcome (19).
Thus, when antibiotics are started within 1 h of documented hypotension, survival is
high (79.9%) and each subsequent hour of delay over the next 6 h is associated with
an average decrease in survival of 7.6%. This means that sCD6 and antibiotics in no way
have the same mechanism of action but rather share a similar therapeutic window.
Accordingly, when imipenem/cilastatin was coadministered with sCD6 (i.p. or i.v.), clear
additive therapeutic effects were evidenced, a fact indicative of different mechanisms
of action. Indeed, the broad-spectrum bactericidal antibiotic used, imipenem/cilastatin,
is a member of the carbapenem class that acts by inhibiting cell wall synthesis of
various G and G bacteria, thus reducing the amount of PAMPs released during
bacteriolysis. This makes it a ﬁrst-choice treatment in critically ill patients with sepsis. It
remains, however, to explore whether the observed additive effects are shared by other
bactericidal or bacteriostatic antibiotics from the same or a different class, since rshCD6
protein-mediated interactions could putatively interfere with their pharmacodynamics
or mechanisms of action.
Lifelong broad-spectrum antibiotic therapy is also a suitable choice for prophylaxis
or treatment of infections in some clinical settings such as congenital or acquired
immune deﬁciencies. However, clinicians must balance the beneﬁts of prophylactic
antibiotic usage with problems such as compliance, adverse reactions, and develop-
ment of antibiotic resistance. In light of these circumstances, the prophylactic effects
achieved by inducing sustained sCD6 levels in plasma through liver-speciﬁc AAV-
mediated expression could be considered for future interventions. The possibility of
sustained high circulating sCD6 levels having deleterious consequences by compro-
mising certain immune cell functions would need to be ﬁrst totally excluded. In this
regard, preliminary characterization of a transgenic mouse line constitutively express-
ing circulating levels of shCD6 generated by our laboratory does not reveal signiﬁcant
harmful immune cell defects.
In order to minimize immunogenicity-related problems related with human pro-
teins, AAV8 coding for mouse sCD6 was used. This allowed to demonstrate that human
sCD6 and mouse sCD6 share similar antibacterial properties, which have been con-
served through evolution. The bacterial binding site/s responsible for such an activity
has not been identiﬁed yet. However, SRCR domains 1 and 3 of both human and mouse
CD6 hold a motif (VEVxxxxxW) previously found in other members of the SRCR-SF as
responsible for their reported bacterial binding properties (20, 21), and this possibility
should be investigated. Similarly, there is no reported evidence on the in vivo func-
tionality in mouse models of infection or sepsis for soluble members of the SRCR-SF
with reported binding and aggregating ability to G and G bacteria (22–25), and this
should be further explored.
In conclusion, the results of the present report open new pathways to explore the
antimicrobial and/or anti-inﬂammatory properties of sCD6 and other soluble SRCR-SF
members in experimental models of mono- or polybacterial infection. Moreover, they
show that sCD6 targeting is a feasible adjunctive strategy to antibiotic therapy as well
as to other nonantibiotic therapies targeting late components of the host inﬂammatory
cascade (e.g., TREM-1 and HMGB-1).
MATERIALS AND METHODS
Expression, puriﬁcation, and biotinylation of recombinant proteins. Production of puriﬁed
rshCD6 and rshCD5 proteins (phosphate-buffered saline [PBS] with 10% glycerol, pH 7.4) was done based
on previously reported methods (25) but using SURE CHO-M Cell line clones from the Selexis SURE-
technology Platform (Geneva, Switzerland) and subjecting serum-free supernatants to size exclusion
chromatography protocols developed at PX’Therapeutics (Grenoble, France).
Cecal ligation and puncture procedure. All animal procedures were approved by the Animal
Experimentation Ethical Committee, University of Barcelona. CLP-induced septic shock was induced in 8-
to 10-week-old C57BL/6J male mice (20 to 25 g; Charles River) as in previously reported methods (26).
The severity of the CLP model was adjusted to achieve a high-grade mortality (90% mortality in the ﬁrst
48 to 72 h) by ligating 75% of cecum. Mice were anesthetized with 100 mg/kg ketamine (Imalgéne 1000;
Merial) and 10 mg/kg xylazine (Rompun; Bayer) and subsequently resuscitated with 1 ml saline serum
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intraperitoneally (i.p.). To mitigate pain effects, 0.05 mg/kg/12 h buprenorphine was administered
subcutaneously. When indicated, imipenem/cilastatin (33 mg/kg/8 h; Actavis, Iceland) and rshCD6 (0.32
to 2.5 mg/kg) were administered i.p. or i.v. The ﬁnal experimental outcome was observation of
spontaneous mortality, which was represented as the percentage of surviving animals over time. Daily
weight loss monitoring (usually 10 to 15% in the ﬁrst 48 h post-CLP) allowed exclusion of animals not
undergoing clinical sepsis.
ELISA measurement of rshCD6 and cytokine levels in plasma. Levels of rshCD6 in plasma were
determined by sandwich enzyme-linked immunosorbent assay (ELISA), using unlabeled 161.8 and
biotin-labeled SPV-L14.2 (2 g/ml, each) as capture and detection anti-CD6 monoclonal antibodies,
respectively. Plasma samples were diluted 1:5, and serial dilutions of puriﬁed rshCD6 were used as a
standard. Plates were developed with horseradish peroxidase-labeled streptavidin (Roche Diagnostics)
and the TMB substrate reagent set (BD OptEIA; BD Biosciences), and optical density at 450 nm (OD450)
was measured. Diluted or undiluted plasma samples were used for monitoring levels of IL-6 (1:70; mouse
IL-6 ELISA set; catalog no. 555240; BD Bioscience), TNF- (1:10; mouse TNF- ELISA set; catalog no.
558534; BD Bioscience), IL-10 (neat; mouse IL-10 ELISA set, catalog no. 555252; BD Bioscience), and IL-1
(neat; mouse IL-1 ELISA set, catalog no. 559603; BD Bioscience) by commercially available ELISA kits,
according to the manufacturer’s instructions.
Recombinant AAV vector construction and virus production and puriﬁcation. Recombinant
AAV8 vectors expressing msCD6 or luciferase protein under the control of the chimeric liver-speciﬁc
promoter formed by the albumin enhancer and human -1-antitrypsin promoter (EalbAAT) were
constructed (27). The cDNA coding for signal peptide from immunoglobulin  light chain variable region
fused in frame with amino acids Gly25-Thr398 from msCD6 (28) was cloned as SalI-NotI into the AAV2
genome, obtaining the plasmid pAAV-EalbAAT-rmsCD6. For AAV-rmsCD6 virus production, a mixture of
pAAV-EalbAAT-rmsCD6 (20 g) and pDP8.ape (55 g; PlasmidFactory GmbH & Co. KG, Bielefeld,
Germany) plasmids was transfected into 15-cm plates seeded with semiconﬂuent 293 T cells using linear
polyethyleneimine (PEI) 25 kDa (Polysciences, Warrington, PA). Cells were harvested 72 h posttransfec-
tion, and virus was released by three rounds of cell freeze-thawing. Crude lysates were treated with
Benzonase (50 U/ml) for 1 h at 37°C and kept at 80°C until puriﬁcation by using iodixanol gradients
according to a previously described method (29). The puriﬁed viral batches were concentrated by
cross-ﬂow ﬁltration and then ﬁltered (0.22 m) and stored at 80°C. Viral titers (in terms of genome
copies per milliliter) were determined by real-time quantitative PCR using primers speciﬁc to the human
-1-antitrypsin promoter (AAT-Forward, 5=-CCCTGTTTGCTCCTCCGATAA-3=, and AAT-Reverse, 5=-GTCCG
TATTTAAGCAGTGGATCCA-3=). For AAV biodistribution studies, mice received a single i.v. dose of 1 
1011 viral particles/mouse (ﬁnal volume, 200 l), and msCD6 plasma levels were monitored by ELISA
(DuoSet mouse CD6; R&D Systems) at different time points.
Statistical analysis. Statistical analyses were performed using the Prism 5.00 computer program
(GraphPad Software Inc., San Diego, CA). The survival data were represented in Kaplan-Meier graphs and
analyzed by the log rank 2 test. Statistically signiﬁcant differences (P  0.01) were determined by the
2-tailed nonparametric Mann-Whitney test.
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